- Home >
- Clinicals Trials >
- TANGENT (SNX-301-020)
Retour à la liste des essais cliniquesSarcomas
TANGENT (SNX-301-020)
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.
- Ouvert à Paris depuis le : 14/02/2025
- Public cible : Adult
- Phase : Phase III
Description de l'essai
The primary efficacy objective of this study is to estimate the treatment effect of emactuzumab by ORR by 6 months from initiation of therapy in the blinded phase compared to placebo.;ORR according to RECIST v1.1 by 6 months from initiation of therapy based on independent, blinded central review
Url of the trial